Iqvia Holdings Inc (IQV) Return on Equity ROE from the first quarter 2026 to first quarter 2025 and annually, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Iqvia Holdings Inc   (NYSE: IQV)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Iqvia Holdings Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Iqvia Holdings Inc in the first quarter 2026?
Iqvia Holdings Inc achieved a return on average equity (ROE) of 22.15 % in its first quarter 2026, this is above IQV's average return on equity of 13.35%.
Iqvia Holdings Inc s equity during the 12 months ending in the first quarter 2026 are valued at $6 billion

While the company's net income was fading, Iqvia Holdings Inc was able to improve its ROE compared to the fourth quarter 2025.

Within the Medical Laboratories industry 4 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2025 from 285 to 592.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Equity Change 6.08 % 9.28 % -9.75 % -13.82 % -
Y / Y Net Income Change 10.44 % 17.62 % 16.49 % -26.72 % -13.54 %
Net Income (TTM) in Millions 1,387 1,361 1,284 1,237 1,334
Return On Equity (TTM) 22.15 % 22.05 % 21.29 % 19.95 % 20.74 %
IQV's Total Ranking # 592 # 285 # 111 # 489 # 249
Equity (TTM) in Millions 6,349 6,630 6,288 5,786 5,985
Seq. Equity Change -4.24 % 5.44 % 8.68 % -3.32 % -1.35 %
Seq. Net Income Change -46.5 % 54.82 % 24.81 % 6.83 % -43.02 %

Back to IQV Management Effectiveness >> IQV's 5 Years Annual ROE >> Compare IQV ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 5
Sector # 75
Overall # 592

Return On Equity Statistics
High Average Low
23.02 %
13.35 %
0.94 %
(Dec 31 2023)   (Sep 30 2017)





IQV Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 6,630 6,067 6,112 5,765 6,042
Y / Y Equity Change 9.28 % -0.74 % 6.02 % -4.58 % -3.79 %
Net Income in Millions 1,361 1,373 1,358 1,091 971
Y / Y Net Income Change -0.87 % 1.1 % 24.47 % 12.36 % 215.26 %
Return On Equity 20.53 % 22.63 % 22.22 % 18.92 % 16.07 %

Back to IQV Management Effectiveness >> IQV's 5 Years Annual ROE >> Compare IQV ROE to its Competitors




Annual Roe Comment
In 2025 ROE decreased compared to the previous year to 20.53 %, due to deterioration of net income.


More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
IQV's' Return on Equity at Yahoo Finance
IQV's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for IQV's Competitors
Subscribers only: Roe for Iqvia Holdings Inc 's Suppliers
Subscribers only: Return On Equity for IQV's Customers




Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector ROE
Dariohealth Corp   60.52 %
Nrc Health  57.25 %
Oramed Pharmaceuticals Inc  55.40 %
Innoviva Inc   47.59 %
Concentra Group Holdings Parent Inc   46.95 %
Liquidia Corporation  46.82 %
Agilent Technologies inc   44.45 %
Tenet Healthcare Corp  44.20 %
Theravance Biopharma inc   43.85 %
Gilead Sciences Inc   42.33 %
Transmedics Group Inc   41.92 %
Abeona Therapeutics Inc   41.40 %
Apellis Pharmaceuticals Inc   39.71 %
Adma Biologics Inc   38.97 %
Bristol myers Squibb Company  38.94 %
Acadia Pharmaceuticals Inc   35.65 %
Spero Therapeutics Inc   35.58 %
Illumina Inc   33.99 %
Dexcom Inc   33.83 %
Rafael Holdings Inc  31.93 %
Solventum Corporation  30.71 %
Phibro Animal Health Corporation  30.60 %
Pro dex Inc   30.01 %
Incyte Corporation  29.20 %
Protalix Biotherapeutics inc   28.10 %
Collegium Pharmaceutical Inc   26.74 %
Pacs Group Inc   26.46 %
Johnson and Johnson  26.26 %
Engene Therapeutics Inc   25.83 %
Encompass Health Corporation  25.56 %

Date modified: 2026-09-26T06:58:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.